Axicabtagene Ciloleucel Approved in Europe for DLBCL, PMBCL

August 27, 2018 – The European Commission has approved axicabtagene ciloleucel (axi-cel) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) or primary mediastinal large B-cell lymphoma (PMBCL), following at least 2 lines of systemic therapy, according to Kite (Gilead), the manufacturer of the CAR T-cell therapy. The approval is based on findings from the single-arm phase II ZUMA-1 trial. Results for the study … (leggi tutto)